Shanghai Medicilon's conservative liability management and light debt load are overshadowed by its loss-making status and shrinking revenue. Despite this, its balance sheet doesn't seem overly risky currently, but may need more capital if break-even isn't reached soon.
Analysts express skepticism despite investors expecting the company to reverse its trend and outperform. The unsustainable level of earnings growth may depress the stock price according to them.
Shanghai Medicilon Inc.に関するコメント
Last Friday, WuXi AppTec's shares tumble by 20% in Hong Kong and fall by a 10% limit-down in mainland China.
Other CRO stocks including Medicilon are also falling.
$薬明生物(02269.HK)$ $無錫薬明康徳(02359.HK)$ $BGI Genomics(300676.SZ)$ $MGI Tech Co., Ltd.(688114.SH)$ $Shanghai Medicilon Inc.(688202.SH)$ $ノボ・ノルディスク(NVO.US)$ $Hang Seng H-Share Index ETF(02828.HK)$
まだコメントはありません